Large R&D-based companies
GSK and Pfizer are joint leaders among the eight large research-based companies evaluated. GSK has the largest R&D pipeline of any of the companies evaluated, and also performs well in enforcing discharge limits along the manufacturing supply chain. Pfizer has made the biggest strides since the previous Benchmark in the scale and scope of its approach to AMR, including by boosting its infectious diseases R&D, and by demonstrating best practice in multiple areas.
Generic medicine manufacturers
Aurobindo, Abbott and Viatris are the leaders among the generic medicine manufacturers, taking steps to combat overselling of antimicrobials. Abbott and Viatris, alongside Cipla, are also the fi rst of this group of companies to report setting discharge limits at their third-party suppliers’ manufacturing sites. Overall, progress by the generic medicine manufacturers can be seen in transparency, stewardship, sales practices, and wider registration of medicines in LMICs.
Small- and medium-sized enterprises (SMEs) were analysed in a separate report published earlier this year.
These smaller companies account for 75% of all late-stage antibiotics in the R&D pipeline. However, they have limited capacity, specifically when compared to large research-based pharmaceutical companies, in planning and facilitating appropriate access and stewardship of products on the market.
This report investigates the SMEs that drive antibiotic and antifungal R&D and their chances of surviving tough financial conditions to bring new medicines to market.